Extended Data Fig. 4: Adverse events.
From: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Patients were monitored for adverse events from the beginning of lymphodepletion (day -4) until day 28 (four weeks post-infusion). Adverse events were described using Common Terminology Criteria for Adverse Events version 4.
